Nephro-Urology Monthly

Published by: Kowsar

The Association Between Erythrocyte Sedimentation Rate, C3, C4, Anti-dsDNA Levels, and Renal Disease Activity, Based on BILAG Index in Females With Lupus Nephritis

Razieh Sadat Mousavi Roknabadi 1 , Negin Hadi 2 , * , Zahra Habib Agahi 3 , Bahareh Rezvan 1 and Ali Mantegh 4
Authors Information
1 Community Medicine Resident, Community Medicine Department, Shiraz University of Medical Sciences, Shiraz, IR Iran
2 MD MPH, Professor of Community Medicine, Community Medicine Department, Neurosciences Research Center, Research Center for Psychiatry and Behavioral Sciences, Shiraz University of Medical Sciences ,Shiraz, IR Iran
3 Assistant Professor of Rheumatology, Internal Medicine Department, Shiraz University of Medical Sciences, Shiraz, IR Iran
4 Medical Student, Shiraz University of Medical Sciences, Shiraz, IR Iran
Article information
  • Nephro-Urology Monthly: March 2018, 10 (2); e63075
  • Published Online: February 19, 2018
  • Article Type: Research Article
  • Received: October 20, 2017
  • Accepted: February 3, 2018
  • DOI: 10.5812/numonthly.63075

To Cite: Mousavi Roknabadi R S, Hadi N, Habib Agahi Z, Rezvan B, Mantegh A. The Association Between Erythrocyte Sedimentation Rate, C3, C4, Anti-dsDNA Levels, and Renal Disease Activity, Based on BILAG Index in Females With Lupus Nephritis, Nephro-Urol Mon. 2018 ; 10(2):e63075. doi: 10.5812/numonthly.63075.

Copyright © 2018, Nephro-Urology Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Methods
3. Results
4. Discussion
  • 1. Agmon-Levin N, Mosca M, Petri M, Shoenfeld Y. Systemic lupus erythematosus one disease or many?. Autoimmun Rev. 2012;11(8):593-5. doi: 10.1016/j.autrev.2011.10.020. [PubMed: 22041578].
  • 2. Smith PP, Gordon C. Systemic lupus erythematosus: clinical presentations. Autoimmun Rev. 2010;10(1):43-5. doi: 10.1016/j.autrev.2010.08.016. [PubMed: 20850569].
  • 3. Von Feldt JM. Systemic lupus erythematosus. Recognizing its various presentations. Postgrad Med. 1995;97(4):79-83, 86 passim. [PubMed: 7716094].
  • 4. Davatchi F, Jamshidi AR, Banihashemi AT, Gholami J, Forouzanfar MH, Akhlaghi M, et al. WHO-ILAR COPCORD Study (Stage 1, Urban Study) in Iran. J Rheumatol. 2008;35(7):1384. [PubMed: 18464299].
  • 5. Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum. 1998;41(5):778-99. doi: 10.1002/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V. [PubMed: 9588729].
  • 6. Chakravarty EF, Bush TM, Manzi S, Clarke AE, Ward MM. Prevalence of adult systemic lupus erythematosus in California and Pennsylvania in 2000: estimates obtained using hospitalization data. Arthritis Rheum. 2007;56(6):2092-4. doi: 10.1002/art.22641. [PubMed: 17530651].
  • 7. Pons-Estel GJ, Alarcon GS, Scofield L, Reinlib L, Cooper GS. Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum. 2010;39(4):257-68. doi: 10.1016/j.semarthrit.2008.10.007. [PubMed: 19136143].
  • 8. Akbarian M, Faezi ST, Gharibdoost F, Shahram F, Nadji A, Jamshidi AR, et al. Systemic lupus erythematosus in Iran: a study of 2280 patients over 33 years. Int J Rheum Dis. 2010;13(4):374-9. doi: 10.1111/j.1756-185X.2010.01547.x. [PubMed: 21199473].
  • 9. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1982;25(11):1271-7. [PubMed: 7138600].
  • 10. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725. doi: 10.1002/1529-0131(199709)40:9&lt;1725::AID-ART29&gt;3.0.CO;2-Y. [PubMed: 9324032].
  • 11. Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, et al. American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res (Hoboken). 2012;64(6):797-808. doi: 10.1002/acr.21664. [PubMed: 22556106].
  • 12. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, et al. Morbidity and mortality in systemic lupus erythematosus during a 10-year period: a comparison of early and late manifestations in a cohort of 1,000 patients. Medicine (Baltimore). 2003;82(5):299-308. doi: 10.1097/ [PubMed: 14530779].
  • 13. Mosca M, Tani C, Aringer M, Bombardieri S, Boumpas D, Brey R, et al. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis. 2010;69(7):1269-74. doi: 10.1136/ard.2009.117200. [PubMed: 19892750].
  • 14. Vila LM, Alarcon GS, McGwin GJ, Bastian HM, Fessler BJ, Reveille JD, et al. Systemic lupus erythematosus in a multiethnic cohort (LUMINA): XXIX. Elevation of erythrocyte sedimentation rate is associated with disease activity and damage accrual. J Rheumatol. 2005;32(11):2150-5. [PubMed: 16265693].
  • 15. Swaak AJ, Groenwold J, Bronsveld W. Predictive value of complement profiles and anti-dsDNA in systemic lupus erythematosus. Ann Rheum Dis. 1986;45(5):359-66. [PubMed: 3487292].
  • 16. Stojan G, Fang H, Magder L, Petri M. Erythrocyte sedimentation rate is a predictor of renal and overall SLE disease activity. Lupus. 2013;22(8):827-34. doi: 10.1177/0961203313492578. [PubMed: 23761098].
  • 17. Bertsias GK, Tektonidou M, Amoura Z, Aringer M, Bajema I, Berden JH, et al. Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. Ann Rheum Dis. 2012;71(11):1771-82. doi: 10.1136/annrheumdis-2012-201940. [PubMed: 22851469].
  • 18. Markowitz GS, D'Agati VD. The ISN/RPS 2003 classification of lupus nephritis: an assessment at 3 years. Kidney Int. 2007;71(6):491-5. doi: 10.1038/ [PubMed: 17264872].
  • 19. Hadi N, Rahmani Z, Montazeri A. Health-related quality of life in chronic renal failure patients receiving hemodialysis. Payesh. 2010;9(4):349-54.
  • 20. Liang MH, Socher SA, Roberts WN, Esdaile JM. Measurement of systemic lupus erythematosus activity in clinical research. Arthritis Rheum. 1988;31(7):817-25. [PubMed: 3293570].
  • 21. Castrejon I, Tani C, Jolly M, Huang A, Mosca M. Indices to assess patients with systemic lupus erythematosus in clinical trials, long-term observational studies, and clinical care. Clin Exp Rheumatol. 2014;32(5 Suppl 85):S-85-95. [PubMed: 25365095].
  • 22. Symmons DP, Coppock JS, Bacon PA, Bresnihan B, Isenberg DA, Maddison P, et al. Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Members of the British Isles Lupus Assessment Group (BILAG). Q J Med. 1988;69(259):927-37. [PubMed: 3271336].
  • 23. Hay EM, Bacon PA, Gordon C, Isenberg DA, Maddison P, Snaith ML, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med. 1993;86(7):447-58. [PubMed: 8210301].
  • 24. Fincher RM, Page MI. Clinical significance of extreme elevation of the erythrocyte sedimentation rate. Arch Intern Med. 1986;146(8):1581-3. [PubMed: 3729639].
  • 25. de Man YA, Hazes JM, van de Geijn FE, Krommenhoek C, Dolhain RJ. Measuring disease activity and functionality during pregnancy in patients with rheumatoid arthritis. Arthritis Rheum. 2007;57(5):716-22. doi: 10.1002/art.22773. [PubMed: 17530669].
  • 26. Nasiri S, Karimifar M, Bonakdar ZS, Salesi M. Correlation of ESR, C3, C4, anti-DNA and lupus activity based on British Isles Lupus Assessment Group Index in patients of rheumatology clinic. Rheumatol Int. 2010;30(12):1605-9. doi: 10.1007/s00296-009-1201-3. [PubMed: 19809816].
  • 27. Gladman DD, Urowitz MB, Keystone EC. Serologically active clinically quiescent systemic lupus erythematosus: a discordance between clinical and serologic features. Am J Med. 1979;66(2):210-5. [PubMed: 218447].
  • 28. Hussain N, Jaffery G, Hasnain S. Serum complement C3 and C4 levels in relation to diagnosis of lupus nephritis. Tropical J Pharmaceutical Res. 2008;7(4):1117-21.
  • 29. Guzman J, Cardiel MH, Arce-Salinas A, Sanchez-Guerrero J, Alarcon-Segovia D. Measurement of disease activity in systemic lupus erythematosus. Prospective validation of 3 clinical indices. J Rheumatol. 1992;19(10):1551-8. [PubMed: 1464867].
  • 30. Wollaston SJ, Farewell VT, Isenberg DA, Gordon C, Merrill JT, Petri MA, et al. Defining response in systemic lupus erythematosus: a study by the Systemic Lupus International Collaborating Clinics group. J Rheumatol. 2004;31(12):2390-4. [PubMed: 15570639].
  • 31. Narayanan K, Marwaha V, Shanmuganandan K, Shankar S. Correlation between Systemic Lupus Erythematosus Disease Activity Index, C3, C4 and Anti-dsDNA Antibodies. Med J Armed Forces India. 2010;66(2):102-7. doi: 10.1016/S0377-1237(10)80118-2. [PubMed: 27365721].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments